A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Trial status:Recruiting
Trial ID:
BNT324-01
NCT ID:
NCT06892548
EudraCT ID:
N/A
EU Trial (CTIS) Number:
2024-520238-31-00
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting

Trial Details

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).

Medical Condition
  • Lung Cancer
    • Trial Drug
  • BNT324
    • See more
  • BNT327
    • Phase
    Phase 1/Phase 2
    Type
    Interventional
    Estimated Enrolment
    594
    Estimated Trial Date
    May 2025 - Aug 2027

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No

    Trial Locations

    Location
    Status
    Location
    Precision NextGen Oncology and Research Center
    Beverly Hills, California, United States, 90212
    Status
    Recruiting
    Location
    Virginia Cancer Specialists
    Fairfax, Virginia, United States, 22031
    Status
    Recruiting